HUE050779T2 - Folyékony gyógyszerészeti készítmény - Google Patents

Folyékony gyógyszerészeti készítmény

Info

Publication number
HUE050779T2
HUE050779T2 HUE15723695A HUE15723695A HUE050779T2 HU E050779 T2 HUE050779 T2 HU E050779T2 HU E15723695 A HUE15723695 A HU E15723695A HU E15723695 A HUE15723695 A HU E15723695A HU E050779 T2 HUE050779 T2 HU E050779T2
Authority
HU
Hungary
Prior art keywords
pharmaceutical preparation
liquid pharmaceutical
liquid
preparation
pharmaceutical
Prior art date
Application number
HUE15723695A
Other languages
English (en)
Hungarian (hu)
Inventor
Gianluca Rinaldi
Silvia Fratarcangeli
Rio Alessandra Del
Original Assignee
Fresenius Kabi Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50774706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE050779(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fresenius Kabi Deutschland Gmbh filed Critical Fresenius Kabi Deutschland Gmbh
Publication of HUE050779T2 publication Critical patent/HUE050779T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hydrogenated Pyridines (AREA)
HUE15723695A 2014-05-23 2015-05-15 Folyékony gyógyszerészeti készítmény HUE050779T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14169755.7A EP2946767B1 (en) 2014-05-23 2014-05-23 Liquid pharmaceutical composition

Publications (1)

Publication Number Publication Date
HUE050779T2 true HUE050779T2 (hu) 2021-01-28

Family

ID=50774706

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15723695A HUE050779T2 (hu) 2014-05-23 2015-05-15 Folyékony gyógyszerészeti készítmény

Country Status (19)

Country Link
US (2) US10426833B2 (enExample)
EP (4) EP2946767B1 (enExample)
JP (3) JP2017516848A (enExample)
CN (2) CN106535935A (enExample)
AU (3) AU2015263247A1 (enExample)
CA (2) CA2948746C (enExample)
CY (1) CY1124493T1 (enExample)
DK (3) DK3145488T3 (enExample)
ES (2) ES2607489T3 (enExample)
HK (1) HK1231391A1 (enExample)
HR (1) HRP20201242T1 (enExample)
HU (1) HUE050779T2 (enExample)
IL (2) IL277241B (enExample)
LT (1) LT3145488T (enExample)
PT (1) PT3145488T (enExample)
RS (1) RS60801B1 (enExample)
SI (1) SI3145488T1 (enExample)
SM (1) SMT202000479T1 (enExample)
WO (1) WO2015177059A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050557A1 (en) 2014-05-23 2016-08-03 Ares Trading S.A. Liquid pharmaceutical composition
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
CN105543204A (zh) * 2015-12-30 2016-05-04 海口奇力制药股份有限公司 一种组合物及其应用、含有该组合物的稳定剂
WO2017177160A1 (en) 2016-04-07 2017-10-12 Nevakar Llc Formulation for use in a method of treatment of pain
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
CN110831621A (zh) * 2017-04-18 2020-02-21 雷迪博士实验室有限公司 稳定的液体药物组合物
WO2019070641A1 (en) * 2017-10-03 2019-04-11 Nevakar Inc. COMBINATIONS OF ACETAMINOPHENE-PRÉGABALINE AND METHODS OF TREATING PAIN
MX2017016884A (es) * 2017-12-19 2019-06-20 Probiomed S A De C V Formulacion farmaceutica estable de una proteina anti-tnfa.
MX2021000790A (es) * 2018-07-20 2021-07-21 Momenta Pharmaceuticals Inc Composiciones de anticuerpos del receptor neonatal para fc y metodos de uso de las mismas.
IL319755A (en) * 2022-10-07 2025-05-01 Annexon Inc Anti-C1Q antibody formulations

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6388197A (ja) 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
CZ292465B6 (cs) 1996-02-09 2003-09-17 Abbott Laboratories (Bermuda) Ltd. Lidské protilátky k lidskému TNFalfa
US5900404A (en) 1997-08-15 1999-05-04 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
ES2349779T5 (es) 2003-04-04 2013-11-26 Genentech, Inc. Formulaciones de anticuerpos y de proteínas a concentración elevada
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
CN101721701A (zh) 2004-07-23 2010-06-09 健泰科生物技术公司 抗体或其片段的结晶
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2006255415B2 (en) 2005-06-07 2011-10-06 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
KR20190045414A (ko) 2007-11-30 2019-05-02 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
BR122018013284B1 (pt) * 2008-10-29 2022-03-03 Ablynx N.V Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab
SG175188A1 (en) 2009-05-04 2011-11-28 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
WO2011104381A2 (en) * 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
KR101853981B1 (ko) 2010-03-01 2018-05-02 사이토딘 인크. 농축 단백질 제형물 및 그의 용도
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
RS55385B1 (sr) 2010-11-11 2017-03-31 Abbvie Biotechnology Ltd Tečna formulacija anti-tnfalfa antitela visoke koncentracije
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
AU2012279205B2 (en) 2011-07-01 2017-08-31 Biogen Ma Inc. Arginine - free TNFR : Fc- fusion polypeptide compositions and methods of use
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
AU2013255413C1 (en) * 2012-03-07 2016-03-24 Cadila Healthcare Limited Pharmaceutical formulations of TNF-alpha antibodies
JP2015519382A (ja) 2012-06-12 2015-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療用抗体のための医薬処方物
DK2892550T3 (da) * 2012-09-07 2020-03-30 Coherus Biosciences Inc Stabile vandige formuleringer af adalimumab
SG11201502659YA (en) 2012-10-25 2015-05-28 Medimmune Llc Stable, low viscosity antibody formulation
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
RU2020139283A (ru) 2012-11-01 2020-12-10 Эббви Инк. Стабильная композиция белка иммуноглобулина с двойными вариабельными доменами
CN104707146B (zh) 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
EP3125928A4 (en) 2014-04-02 2017-11-29 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
ES2572919T3 (es) * 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
EP3050557A1 (en) 2014-05-23 2016-08-03 Ares Trading S.A. Liquid pharmaceutical composition

Also Published As

Publication number Publication date
CA3104940A1 (en) 2015-11-26
JP2022174082A (ja) 2022-11-22
WO2015177059A1 (en) 2015-11-26
IL249116B (en) 2020-09-30
EP3741358A1 (en) 2020-11-25
IL277241B (en) 2022-08-01
AU2015263247A1 (en) 2016-12-01
CN111939257A (zh) 2020-11-17
PT3145488T (pt) 2020-09-01
ES2607489T3 (es) 2017-03-31
AU2020286276B2 (en) 2023-06-01
JP2021107399A (ja) 2021-07-29
CA2948746C (en) 2021-01-12
RS60801B1 (sr) 2020-10-30
DK202000038Y3 (da) 2020-07-10
HK1231391A1 (zh) 2017-12-22
AU2020204269B2 (en) 2020-09-17
IL249116A0 (en) 2017-01-31
EP3145488B1 (en) 2020-07-22
CA2948746A1 (en) 2015-11-26
US10426833B2 (en) 2019-10-01
EP3939566A1 (en) 2022-01-19
EP3145488A1 (en) 2017-03-29
EP2946767A1 (en) 2015-11-25
US20200155677A1 (en) 2020-05-21
CY1124493T1 (el) 2022-03-24
EP2946767B1 (en) 2016-10-05
ES2815598T3 (es) 2021-03-30
DK202000030U1 (da) 2020-04-28
JP2017516848A (ja) 2017-06-22
LT3145488T (lt) 2020-11-25
AU2020286276A1 (en) 2021-01-14
SI3145488T1 (sl) 2020-10-30
DK3145488T3 (da) 2020-08-10
AU2020204269A1 (en) 2020-07-16
DK202000038U1 (da) 2020-05-18
DK202000030Y3 (da) 2020-05-26
SMT202000479T1 (it) 2020-11-10
US20170182162A1 (en) 2017-06-29
HRP20201242T1 (hr) 2020-11-13
IL277241A (en) 2020-10-29
CN106535935A (zh) 2017-03-22

Similar Documents

Publication Publication Date Title
IL282481A (en) A liquid pharmaceutical preparation
DK3479819T3 (da) Stabilt væskeformigt farmaceutisk præparat
HUE054344T2 (hu) Gyógyászati készítmények AZD9291 tartalommal
DK3171921T3 (da) Lægemiddelafgivelsesindretning
DK3494962T3 (da) Flydende inhalationsformulering omfattende RPL554
HUE045234T2 (hu) Gyógyszeradagolás tanulása
DK3145836T3 (da) Dispenseringskapsel
DK3199161T3 (da) Farmaceutisk præparat
IL277241A (en) A liquid pharmaceutical preparation
DK3532029T3 (da) Flydende farmaceutisk sammensætning
IL249117A0 (en) A liquid pharmaceutical preparation
DK2992967T3 (da) Medikamentdispenser
DK3215118T3 (da) Lægemiddelanordningsenhed indeholdende quinagolid
HUE050881T2 (hu) Gyógyszerkészítmény
EP3217965C0 (en) Pharmaceutical processing
HUE047581T2 (hu) Készítmény
EP3181125C0 (en) CAPSULE FORMULATION
DK3288967T3 (da) Farmaceutisk forbindelse
HUE054775T2 (hu) Benzidamint tartalmazó gyógyászati készítmény
TH1601003393A (th) รูปแบบปริมาณที่ให้ทางเภสัชกรรม
DK3288966T3 (da) Farmaceutisk forbindelse
TH1501007302A (th) ยาเตรียมทางเภสัชกรรม
UA29829S (uk) Пляшка для лікарських засобів
UA27515S (uk) Пляшка для лікарських засобів
UA27616S (uk) Пляшка для лікарських засобів